Press Releases

WILMINGTON, Del., January 17, 2023 – Ashland has launched saffragyl ™ biofunctional that transforms oral health into a daily beauty regimen by proposing a natural, safe, and effective bioactive to take care of the biology of the gingiva. Saffragyl ™ biofunctional is a new, COSMOS approved cosmetic

WILMINGTON, Del., Nov. 18, 2022 (GLOBE NEWSWIRE) --  The board of directors of Ashland Inc. (NYSE: ASH) has declared a quarterly cash dividend of $0.335 cents per share on the company's common stock. The dividend is payable on December 15, 2022, to stockholders of record at the close of business on

Sales of $631 million, up 7 percent from the prior-year quarter Net income (including discontinued operations) of $57 million, or $1.04 per diluted share Income from continuing operations of $60 million, or $1.09 per diluted share Adjusted income from continuing operations excluding intangibles

WILMINGTON, Del., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) has been named among the 100 Best ESG Companies by Investor’s Business Daily (IBD). The recognized companies of 2022 include a combination of profitability with environment, social and governance (ESG) responsibility.

WILMINGTON, Del., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) has been recognized with the Commitment to Life Award in the Human Rights category by Natura&Co for Ashland’s Responsible Solvers ™ sustainable guar farming and education program using science, technology, engineering, and

WILMINGTON, Del., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) has earned EcoVadis Gold underscoring the company’s commitment to environment, social and governance (ESG) and a conscious-to-cutting-edge approach to innovation.   Since its founding in 2007, EcoVadis, one of the world’s

New product to be featured in interactive innovation zones within company booth 3755 during SupplySide West tradeshow

WILMINGTON, Del., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE: ASH) today announced the United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research Office of New Drugs has accepted Ashland Viatel ™ bioresorbable mPEG-PDLLA pharmaceutical excipient in the review